Table 4.
Perioperative outcomes.
| Patients (n = 29) | |
|---|---|
| Surgical conversion rate, n/N (%) | 29/55 (52.7%) |
| Cycles of CAM + LEN, median (IQR) | 3 (2–4) |
| Number of TACE, median (IQR) | 1 (1–2) |
| Time from the start of triple therapy to surgical resection (months), median (IQR) | 2.8 (1.8,3.4) |
| Surgical type, n (%) | |
| Laparoscopic | 6 (20.7%) |
| Open | 23 (79.3%) |
| Operative time (h), mean ± SD | 3.7 ± 1.1 |
| Blood loss (mL), median (IQR) | 300 (200, 400) |
| Difficulty of operation, n (%) | |
| Increased | 0 |
| Not increased | 29 (100%) |
| R0 resection rate, n (%) | 28 (96.6%) |
| R1resection rate, n (%) | 1 (3.4%) |
| pCR, n (%) | 6 (20.7%) |
| MPR, n (%) | 19 (65.5%) |
| Clavien-Dindo classification, n (%) | |
| 0-II | 28 (96.6%) |
| III-V | 1 (3.4%) |
| Postoperative hospital stays (days), median (IQR) | 10 (8.5, 13) |
CAM, camrelizumab; LEN, lenvatinib; TACE, transcatheter arterial chemoembolisation; pCR, pathologic complete response; MPR, major pathologic response.